ArticleAdvances in experimental medicine and biology2026
Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.
Article in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lymphocytic leukemia (CLL) progression critically depends on bidirectional communication between malignant B cells and non-malignant bystander cells within the tumor microenvironment, including stromal cells, macrophages, and T lymphocytes. Among the key regulators of this cross talk is the Src-family kinase Lyn, whose activity in stromal cells controls extracellular matrix remodeling, fibrotic niche formation, and the release of tumor-supportive extracellular vesicles (EVs). This chapter presents a comprehensive proteomics-based strategy to identify Lyn-dependent effector molecules conveyed by stromal-cell-derived EVs and to evaluate their functional relevance for leukemic cell survival. State-of-the-art EV purification methods compliant with the Minimal information for studies of extracellular vesicles (MISEV) guidelines, nanoparticle tracking analysis, and high-resolution Orbitrap mass spectrometry are integrated with CRISPR-mediated Lyn knockout models and functional co-culture assays using primary CLL cells. Comparative metaproteomic profiling of EVs from Lyn-proficient and Lyn-deficient stromal cells reveals profound alterations in extracellular matrix proteins, adhesion molecules, redox regulators, and signaling mediators, highlighting downstream pathways through which Lyn programs a tumor-supportive microenvironment. Bioinformatic network analysis and pathway enrichment further identify druggable candidate proteins, including matricellular components and integrin-associated anchors such as CD248, as potential therapeutic nodes. Collectively, this chapter illustrates how EV-focused proteomics enables the systematic dissection of microenvironment-driven oncogenic signaling and provides a translational framework for discovering actionable stromal targets in CLL and other Lyn-dependent malignancies.
Indexed as
Identifiers
42401775What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.